Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11780366 | 0.87 | RAB9A (0.55) | RAB9ANPC1PPIAKMT2ASMN1; SMN2 | |
| SCHEMBL10490780 | 0.79 | KMT2A (0.59) | RAB9ANPC1PPIAHTTKMT2A | |
| SCHEMBL2299040 | 0.77 | IDO1 (0.58) | RAB9ANPC1HTTALDH1A1HTR2A | |
| SCHEMBL87044 | 0.77 | POLB (0.61) | RAB9ANPC1PPIAHTTKMT2A | |
| SCHEMBL11161448 | 0.74 | IDO1 (0.54) | RAB9AHTTHDAC6ALDH1A1HTR2A | |
| SCHEMBL11161443 | 0.74 | IDO1 (0.54) | RAB9AHTTALDH1A1HTR2A | |
| SCHEMBL9524996 | 0.74 | CXCR1 (0.60) | RAB9ANPC1HDAC6KMT2AMEN1 | |
| SCHEMBL3048489 | 0.74 | ALDH1A1 (0.57) | RAB9ANPC1PPIAHTTKMT2A | |
| SCHEMBL6672269 | 0.74 | RAB9A (0.61) | RAB9ANPC1KMT2AALDH1A1MEN1 | |
| SCHEMBL10825508 | 0.74 | DPP8 (0.54) | RAB9AHTTALDH1A1SMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | RAB9A 1172/4885NPC1 2641/4885PPIA 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.